Zacks.com on MSN
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results